Trial Profile
A Phase II Study of Carboplatin+weekly Paclitaxel+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous, non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 02 Jul 2012 Planned end date (Nov 2014) added as reported by University Hospital Medical Information Network - Japan.
- 10 Dec 2011 Status changed from not stated to recruiting as reported by University Hospital Medical Information Network - Japan.